Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Linkers in fragment-based drug design: an overview of the literature

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

DRlinker: Deep Reinforcement Learning for Optimization in Fragment Linking Design

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery

Equivariant 3D-Conditional Diffusion Models for Molecular Linker Design

Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Equivariant 3D-conditional diffusion model for molecular linker design

Concepts and Core Principles of Fragment-Based Drug Design

LinkerNet: Fragment Poses and Linker Co-Design with 3D Equivariant Diffusion

A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors

In silico construction of a focused fragment library facilitating exploration of chemical space**

Application of Fragment-Based Drug Discovery to Versatile Targets

Recent Advances in the Linkers of Drug Conjugates

Fragment-based drug discovery for disorders of the central nervous system: designing better drugs piece by piece

Molecular docking as a popular tool in drug design, an in silico travel

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

iFLinkC: an iterative functional linker cloning strategy for the combinatorial assembly and recombination of linker peptides with functional domains

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology